This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | MicrobiomeTrials
← Back to trials NCT07664735
A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-30Est. Completion: 2030-06
Enrollment target: 30 participantsLocations UCSF - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States Emory - Winship Cancer Institute, Atlanta, Georgia, United States Karmanos Cancer Institute, Detroit, Michigan, United States University of Minnesota, Minneapolis, Minnesota, United States MD Anderson Cancer Center, Houston, Texas, United States Other microbiome trials you might be interested in Recurrent or Metastatic Solid Tumors
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: …
Los Angeles, United States Est. completion Jul 25, 2028
Advanced Malignant Solid Neoplasm Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Locally Advanced Malignant Solid Neoplasm Malignant Female Reproductive System Neoplasm Metastatic HER2-Negative Breast Carcinoma
Metastatic Malignant Solid Neoplasm
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Malignant Female Reproductive System Neoplasm
Recurrent Malignant Solid Neoplasm
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Unresectable HER2-Negative Breast Carcinoma
Unresectable Malignant Solid Neoplasm
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment…
Birmingham, United States Est. completion Jul 1, 2030